Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Continuous WNT Control Enables Advanced hPSC Cardiac Processing and Prognostic Surface Marker Identification in Chemically Defined Suspension Culture.

Halloin C, Schwanke K, Löbel W, Franke A, Szepes M, Biswanath S, Wunderlich S, Merkert S, Weber N, Osten F, de la Roche J, Polten F, Christoph Wollert K, Kraft T, Fischer M, Martin U, Gruh I, Kempf H, Zweigerdt R.

Stem Cell Reports. 2019 Oct 8;13(4):775. doi: 10.1016/j.stemcr.2019.09.001. No abstract available.

PMID:
31597111
2.

Generation of a CFTR knock-in reporter cell line (MHHi006-A-1) from a human induced pluripotent stem cell line.

Engels L, Olmer R, de la Roche J, Göhring G, Ulrich S, Haller R, Martin U, Merkert S.

Stem Cell Res. 2019 Aug 20;40:101542. doi: 10.1016/j.scr.2019.101542. [Epub ahead of print]

3.

Continuous WNT Control Enables Advanced hPSC Cardiac Processing and Prognostic Surface Marker Identification in Chemically Defined Suspension Culture.

Halloin C, Schwanke K, Löbel W, Franke A, Szepes M, Biswanath S, Wunderlich S, Merkert S, Weber N, Osten F, de la Roche J, Polten F, Christoph Wollert K, Kraft T, Fischer M, Martin U, Gruh I, Kempf H, Zweigerdt R.

Stem Cell Reports. 2019 Aug 13;13(2):366-379. doi: 10.1016/j.stemcr.2019.06.004. Epub 2019 Jul 25. Erratum in: Stem Cell Reports. 2019 Oct 8;13(4):775.

4.

Generation of a NKX2.1 knock-in reporter cell line from human induced pluripotent stem cells (MHHi006-A-2).

Olmer R, Dahlmann J, Merkert S, Baus S, Göhring G, Martin U.

Stem Cell Res. 2019 Aug;39:101492. doi: 10.1016/j.scr.2019.101492. Epub 2019 Jun 28.

5.

High-Throughput Screening for Modulators of CFTR Activity Based on Genetically Engineered Cystic Fibrosis Disease-Specific iPSCs.

Merkert S, Schubert M, Olmer R, Engels L, Radetzki S, Veltman M, Scholte BJ, Zöllner J, Pedemonte N, Galietta LJV, von Kries JP, Martin U.

Stem Cell Reports. 2019 Jun 11;12(6):1389-1403. doi: 10.1016/j.stemcr.2019.04.014. Epub 2019 May 9.

6.

Author Correction: Reprogramming triggers endogenous L1 and Alu retrotransposition in human induced pluripotent stem cells.

Klawitter S, Fuchs NV, Upton KR, Muñoz-Lopez M, Shukla R, Wang J, Garcia-Cañadas M, Lopez-Ruiz C, Gerhardt DJ, Sebe A, Grabundzija I, Merkert S, Gerdes P, Pulgarin JA, Bock A, Held U, Witthuhn A, Haase A, Sarkadi B, Löwer J, Wolvetang EJ, Martin U, Ivics Z, Izsvák Z, Garcia-Perez JL, Faulkner GJ, Schumann GG.

Nat Commun. 2018 Dec 19;9(1):5398. doi: 10.1038/s41467-018-07917-0.

7.

Generation of a human CDX2 knock-in reporter iPSC line (MHHi007-A-1) to model human trophoblast differentiation.

Malysheva SV, Wunderlich S, Haase A, Göhring G, Martin U, Merkert S.

Stem Cell Res. 2018 Jul;30:117-121. doi: 10.1016/j.scr.2018.05.015. Epub 2018 May 19.

8.

Impaired IFNγ-Signaling and Mycobacterial Clearance in IFNγR1-Deficient Human iPSC-Derived Macrophages.

Neehus AL, Lam J, Haake K, Merkert S, Schmidt N, Mucci A, Ackermann M, Schubert M, Happle C, Kühnel MP, Blank P, Philipp F, Goethe R, Jonigk D, Martin U, Kalinke U, Baumann U, Schambach A, Roesler J, Lachmann N.

Stem Cell Reports. 2018 Jan 9;10(1):7-16. doi: 10.1016/j.stemcr.2017.11.011. Epub 2017 Dec 14.

9.

Targeted Gene Editing in Human Pluripotent Stem Cells Using Site-Specific Nucleases.

Merkert S, Martin U.

Adv Biochem Eng Biotechnol. 2018;163:169-186. doi: 10.1007/10_2017_25. Review.

PMID:
29124278
10.

Generation of a gene-corrected isogenic control iPSC line from cystic fibrosis patient-specific iPSCs homozygous for p.Phe508del mutation mediated by TALENs and ssODN.

Merkert S, Bednarski C, Göhring G, Cathomen T, Martin U.

Stem Cell Res. 2017 Aug;23:95-97. doi: 10.1016/j.scr.2017.07.010. Epub 2017 Jul 11.

11.

Ex vivo Generation of Genetically Modified Macrophages from Human Induced Pluripotent Stem Cells.

Ackermann M, Kuhn A, Kunkiel J, Merkert S, Martin U, Moritz T, Lachmann N.

Transfus Med Hemother. 2017 Jun;44(3):135-142. doi: 10.1159/000477129. Epub 2017 May 16.

12.

Site-Specific Genome Engineering in Human Pluripotent Stem Cells.

Merkert S, Martin U.

Int J Mol Sci. 2016 Jun 24;17(7). pii: E1000. doi: 10.3390/ijms17071000. Review.

13.

Targeted genome engineering using designer nucleases: State of the art and practical guidance for application in human pluripotent stem cells.

Merkert S, Martin U.

Stem Cell Res. 2016 Mar;16(2):377-86. doi: 10.1016/j.scr.2016.02.027. Epub 2016 Feb 11. Review.

14.

Reprogramming triggers endogenous L1 and Alu retrotransposition in human induced pluripotent stem cells.

Klawitter S, Fuchs NV, Upton KR, Muñoz-Lopez M, Shukla R, Wang J, Garcia-Cañadas M, Lopez-Ruiz C, Gerhardt DJ, Sebe A, Grabundzija I, Merkert S, Gerdes P, Pulgarin JA, Bock A, Held U, Witthuhn A, Haase A, Sarkadi B, Löwer J, Wolvetang EJ, Martin U, Ivics Z, Izsvák Z, Garcia-Perez JL, Faulkner GJ, Schumann GG.

Nat Commun. 2016 Jan 8;7:10286. doi: 10.1038/ncomms10286. Erratum in: Nat Commun. 2018 Dec 19;9(1):5398.

15.

Efficient designer nuclease-based homologous recombination enables direct PCR screening for footprintless targeted human pluripotent stem cells.

Merkert S, Wunderlich S, Bednarski C, Beier J, Haase A, Dreyer AK, Schwanke K, Meyer J, Göhring G, Cathomen T, Martin U.

Stem Cell Reports. 2014 Jan 14;2(1):107-18. doi: 10.1016/j.stemcr.2013.12.003. eCollection 2014 Jan 14.

16.

Primate iPS cells as tools for evolutionary analyses.

Wunderlich S, Kircher M, Vieth B, Haase A, Merkert S, Beier J, Göhring G, Glage S, Schambach A, Curnow EC, Pääbo S, Martin U, Enard W.

Stem Cell Res. 2014 May;12(3):622-9. doi: 10.1016/j.scr.2014.02.001. Epub 2014 Feb 8.

17.

Fast and efficient multitransgenic modification of human pluripotent stem cells.

Schwanke K, Merkert S, Kempf H, Hartung S, Jara-Avaca M, Templin C, Göhring G, Haverich A, Martin U, Zweigerdt R.

Hum Gene Ther Methods. 2014 Apr;25(2):136-53. doi: 10.1089/hgtb.2012.248. Epub 2014 Mar 21.

18.

Gene correction of human induced pluripotent stem cells repairs the cellular phenotype in pulmonary alveolar proteinosis.

Lachmann N, Happle C, Ackermann M, Lüttge D, Wetzke M, Merkert S, Hetzel M, Kensah G, Jara-Avaca M, Mucci A, Skuljec J, Dittrich AM, Pfaff N, Brennig S, Schambach A, Steinemann D, Göhring G, Cantz T, Martin U, Schwerk N, Hansen G, Moritz T.

Am J Respir Crit Care Med. 2014 Jan 15;189(2):167-82. doi: 10.1164/rccm.201306-1012OC.

PMID:
24279725
19.

Induction of pluripotent stem cells from a cynomolgus monkey using a polycistronic simian immunodeficiency virus-based vector, differentiation toward functional cardiomyocytes, and generation of stably expressing reporter lines.

Wunderlich S, Haase A, Merkert S, Beier J, Schwanke K, Schambach A, Glage S, Göhring G, Curnow EC, Martin U.

Cell Reprogram. 2012 Dec;14(6):471-84. doi: 10.1089/cell.2012.0041.

20.

Derivation and characterization of sleeping beauty transposon-mediated porcine induced pluripotent stem cells.

Kues WA, Herrmann D, Barg-Kues B, Haridoss S, Nowak-Imialek M, Buchholz T, Streeck M, Grebe A, Grabundzija I, Merkert S, Martin U, Hall VJ, Rasmussen MA, Ivics Z, Hyttel P, Niemann H.

Stem Cells Dev. 2013 Jan 1;22(1):124-35. doi: 10.1089/scd.2012.0382. Epub 2012 Nov 2.

PMID:
22989381
21.

Long term expansion of undifferentiated human iPS and ES cells in suspension culture using a defined medium.

Olmer R, Haase A, Merkert S, Cui W, Palecek J, Ran C, Kirschning A, Scheper T, Glage S, Miller K, Curnow EC, Hayes ES, Martin U.

Stem Cell Res. 2010 Jul;5(1):51-64. doi: 10.1016/j.scr.2010.03.005. Epub 2010 Mar 30.

22.

Efficient ZFN-based gene inactivation in transgenic human iPS cells as a model for gene editing in patient-specific cells.

Merkert S, Khan K, Haase A, Schwanke K, Cathomen T, Martin U.

J Stem Cells Regen Med. 2010 Oct 23;6(2):118. eCollection 2010. No abstract available.

PMID:
24693131
23.

Efficient multi-genetic modification of human ESC and iPS cells for cardiomyocytes enrichment and tracking.

Schwanke K, Müller S, Merkert S, Martin U, Zweigerdt R.

J Stem Cells Regen Med. 2010 Oct 23;6(2):93. eCollection 2010. No abstract available.

PMID:
24693110
24.

Generation of induced pluripotent stem cells from human cord blood.

Haase A, Olmer R, Schwanke K, Wunderlich S, Merkert S, Hess C, Zweigerdt R, Gruh I, Meyer J, Wagner S, Maier LS, Han DW, Glage S, Miller K, Fischer P, Schöler HR, Martin U.

Cell Stem Cell. 2009 Oct 2;5(4):434-41. doi: 10.1016/j.stem.2009.08.021.

25.

A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo.

von Strandmann EP, Hansen HP, Reiners KS, Schnell R, Borchmann P, Merkert S, Simhadri VR, Draube A, Reiser M, Purr I, Hallek M, Engert A.

Blood. 2006 Mar 1;107(5):1955-62. Epub 2005 Oct 6.

PMID:
16210338

Supplemental Content

Loading ...
Support Center